Drugs / B. Breve HA-129
last change Dec 2020 re-read 2 minutes ago

B. Breve HA-129

Investigated by
Lallemand Health Solutions · University of Florida

Trials 1 · a red edge is where a trial was stopped

2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT04065503 Dec 2019 → Feb 2020 University of Florida Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as B. Breve HA-129 “A commercial product containing L. helveticus R0052, L. casei HA-108, B. breve HA-129, and B. longum R0175 and S. thermophilus HA-110 be given to healthy adults across a...” NCT04065503
1

“Detection and Persistence of a Product Containing L. Helveticus R-0052, L. Casei HA-108, B. Breve HA-129, B. Longum R-0175 and S. Thermophilus HA-110 in Healthy Adults: an...” NCT04065503